Medical Information
Saudi Arabia
 

This medical Information website is intended only for Healthcare Professionals in the Kingdom of Saudi Arabia. This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient.

Please choose the category that best describes you.

This content is intended for Healthcare professionals in Saudi Arabia. Would you like to proceed?

I am a healthcare professional registered to practice in KSAYes, I am a healthcare professional registered to practice in KSA
SelectI am a healthcare professional registered to practice in KSAYes, I am a healthcare professional registered to practice in KSA
I am not a healthcare professionalNo, go back to the patient portal
SelectI am not a healthcare professionalNo, go back to the patient portal
Non-Saudi Arabia residents click here.

Congress Materials

The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Poster
Alidoost M, Nickens DJ, Alhadab A March 18, 2022 ASCPT 2022 Other/Multi-Tumor

Machine Learning (ML) Methods for Progression-Free Survival (PFS) and Overall Survival (OS) Prediction: Reanalysis of JAVELIN Head and Neck 100 Data

View Presentation
Poster
Zhou L, Liao K, Yin D, Chen X, Masters JC March 18, 2022 ASCPT 2022 Other/Multi-Tumor

Population Pharmacokinetics of Sasanlimab in Patients With Solid Tumors: Modeling-Based Analysis of Data From the First-in-Patient Trial

View Presentation
Poster
Laetsch TW, Janeway KA, Hawkins DS, Juszczak-Kosela K, Muscal JA, Collier AB June 5, 2022 ASCO 2022 Other/Multi-Tumor

Randomized Phase 2 Study to Evaluate Palbociclib (IBRANCE®) in Combination with Irinotecan and Temozolomide in Pediatric Patients with Recurrent or Refractory Ewing Sarcoma 

View Presentation View Abstract Plain Language Summary
Poster
Chawla SP, Kelly CM, Gordon EM, Quon DV, Moradkhani A, Chua VS, Thompson TM, Scheuber A, Bruns I, Allgood VE, Movva S June 5, 2022 ASCO 2022 Other/Multi-Tumor

TTI-621-03: A Phase 1/2 Study of TTI-621 in Combination with Doxorubicin in Patients with Unresectable or Metastatic High-Grade Leiomyosarcoma (LMS) 

View Presentation
Poster
Schweizer MT, Penkov K, Tolcher A, Choudhury AD, Doronin V, Aljumaily RM, Calvo E, Frank RC, Hamm J, Moreno V, Vorobyev V, Billotte S, Bowler T, Chen J, Lin T, Liu L, Maity AK, Sharma S, Johnson M September 11, 2022 ESMO 2022 Other/Multi-Tumor

Phase I Trial of PF-06821497, a Potent and Selective Inhibitor of Enhancer of Zeste Homolog 2, in Follicular Lymphoma, Small-Cell Lung Cancer, and Castration-Resistant Prostate Cancer

View Presentation View Abstract Plain Language Summary